NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While revenue and gross margin have improved, the company still reports a net loss. Regulatory risks and uncertainties regarding 2026 financial goals may cause investor caution. The absence of a shareholder return plan or new partnerships limits positive catalysts. The market might react neutrally, awaiting further clarity on regulatory outcomes and financial performance.
Key Financial Performance
Revenue Revenue for Q1 2026 was $15.2 million, representing a 12% increase year-over-year. This growth was driven by higher adoption rates of our RNS System and increased utilization among existing customers.
Gross Margin Gross margin improved to 72% in Q1 2026, up from 68% in Q1 2025. The improvement was attributed to better manufacturing efficiencies and cost reductions in production.
Operating Expenses Operating expenses were $10.5 million in Q1 2026, a 5% increase compared to Q1 2025. The increase was primarily due to higher investments in R&D and sales and marketing initiatives.
Net Loss Net loss for Q1 2026 was $3.8 million, compared to $4.5 million in Q1 2025. The reduction in net loss was due to higher revenue and improved gross margins.
Cash and Cash Equivalents Cash and cash equivalents stood at $45 million as of the end of Q1 2026, compared to $50 million at the end of Q1 2025. The decrease was due to ongoing investments in growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Matters: Risks associated with the IGE PMA-Supplement and other regulatory matters that could impact the company's operations and profitability.
Financial Outlook: Uncertainties in achieving the financial outlook for 2026, which could affect operating performance and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Financial Outlook for 2026: Comments regarding our financial outlook for 2026, our commercial strategy, clinical and product development initiatives, regulatory matters, including our IGE PMA-Supplement and our expectations regarding operating performance and profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO President
Celine Lozada
Director Patrick
Division Frank
Division PM
Division Petrone
Division Polark
Division Priya
EDT Lilia
Forward statement
Frank Takkinen
Head Investor
Instructions conference
Investor Relations
Joel Becker
LLC Ladies
LLC Research
Lilia Celine
Lozada JPMorgan
Mizuho Securities
PM EDT
Patrick Williams
Petrone Mizuho
Polark Wolfe
Priya Sachdeva
Relations Forward
Relations Joel
Research Division
Research LLC
Securities USA
USA LLC
conference Head
name conference
NPCE Transcript
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents a mixed outlook. While revenue and gross margin have improved, the company still reports a net loss. Regulatory risks and uncertainties regarding 2026 financial goals may cause investor caution. The absence of a shareholder return plan or new partnerships limits positive catalysts. The market might react neutrally, awaiting further clarity on regulatory outcomes and financial performance.
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript
Positive3-3
NeuroPace's earnings call reveals strong financial performance with significant revenue and gross margin growth, positive adjusted EBITDA, and reduced net loss. The raised revenue and gross margin guidance for 2025 further indicates optimism. Despite increased operating expenses, the strategic focus on RNS and upcoming FDA submissions, combined with favorable analyst sentiment, supports a positive outlook. The Q&A section highlights the potential of generalized epilepsy opportunities and Project CARE's growth contribution, reinforcing positive sentiment. Given these factors, a positive stock price reaction is expected over the next two weeks.
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary shows positive revenue and gross margin guidance, strong clinical trial results, and AI tool launches. Despite some uncertainties in the Q&A, such as lack of specific milestones in partnerships and unclear responses, the raised guidance and strategic initiatives suggest a positive outlook. The positive sentiment is further supported by optimistic growth expectations and strategic focus on RNS expansion. Given these factors, the stock price is likely to experience a positive movement in the short term.
NPCE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
